The King's Brief Interstitial Lung Disease (KBILD) questionnaire: An updated minimal clinically important difference

BMJ Open Respiratory Research

Volumn 6, Issue 1, 2019, Pages

  Sinha, Aish ^a,b   Patel, Amit Suresh ^b   Siegert, Richard J ^c   Bajwah, Sabrina ^d   Maher, Toby M ^e,f   Renzoni, Elizabeth A ^e   Wells, Athol U ^e   Higginson, Irene J ^d   Birring, Surinder S ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c AUCKLAND UNIVERSITY OF TECHNOLOGY   (New Zealand)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e ROYAL BROMPTON HOSPITAL   (United Kingdom)

^f NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

global rating of change questionnaire; health related quality of life; interstitial lung disease; king's brief Interstitial lung disease questionnaire; minimal clinically important difference

Indexed keywords

ADULT; ARTICLE; DYSPNEA; FEMALE; GLOBAL RATING OF CHANGE QUESTIONNAIRE; HEALTH STATUS; HUMAN; INTERSTITIAL LUNG DISEASE; KINGS BRIEF INTERSTITIAL LUNG DISEASE QUESTIONNAIRE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MIDDLE AGED; OUTPATIENT DEPARTMENT; PATIENT HEALTH QUESTIONNAIRE 15; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; RESPIRATORY FUNCTION DISORDER;

EID: 85061900372     PISSN: None     EISSN: 20524439     Source Type: Journal    
DOI: 10.1136/bmjresp-2018-000363     Document Type: Article

References (18)

1. Patel AS, Siegert RJ, Brignall K, et al. The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire. Thorax 2012;67:804-10.
2. Patel AS, Siegert RJ, Keir GJ, et al. The minimal important difference of the King's Brief Interstitial Lung Disease Questionnaire (K-BILD) and forced vital capacity in interstitial lung disease. Respir Med 2013;107:1438-43.
3. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. ascertaining the minimal clinically important difference. Control Clin Trials 1989;10:407-15.
4. Patel AS, Siegert RJ, Bajwah S, et al. Rasch analysis and impact factor methods both yield valid and comparable measures of health status in interstitial lung disease. J Clin Epidemiol 2015;68:1019-27.
5. Sinha A, Bajwah S, Gosker H, et al. A comparison of two scoring methods for the King's brief interstitial lung disease questionnaire. Eur Respir J 2016;46.
6. Visca D, Tsipouri V, Mori L, et al. Ambulatory oxygen in fibrotic lung disease (AmbOx): Study protocol for a randomised controlled trial. Trials 2017;18:201.
7. ClinicalTrials. gov [Internet]. Hoffmann-La Roche: National Library of Medicine (US). Identifier NCT03261037. An international study to characterize the disease behavior of idiopathic pulmonary fibrosis (IPF) and interstitial lung disease (ILD) during the peri-diagnostic period, 2017.
8. ClinicalTrials. gov [Internet]. Boehringer Ingelheim: National Library of Medicine (US). In: Identifier NCT02999178. A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nintedanib over 52 weeks in patients with progressive fibrosing interstitial lung disease PF-ILD, 2017.
9. Guyatt GH EF, Willan A, Griffith LE. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994;47:81e7.
10. Revicki DA, Cella D, Hays RD, et al. Responsiveness and minimal important differences for patient reported outcomes. Health Qual Life Outcomes 2006;4:70.
11. Swigris JJ, Brown KK, Behr J, et al. The SF-36 and SGRQ: Validity and first look at minimum important differences in IPF. Respir Med 2010;104:296-304.
12. Cohen JAssociates LE, Hillsdale NJ, eds. Statistical power analysis for the behavioral sciences. 2nd edn, 1988.
13. Standardizationof spirometry, 1994 update. American Thoracic Society. Am J Respir Crit Care Med 1995;152:1107e36.
14. Boone WJ. Rasch analysis for instrument development: why, when, and how?. LSE 2016;15:rm4.
15. du Toit R, Palagyi A, Ramke J, et al. Development and validation of a vision-specific quality-of-life questionnaire for Timor-Leste. Invest Ophthalmol Vis Sci 2008;49:4284-9.
16. Ndosi M, Alcacer-Pitarch B, Allanore Y, et al. Common measure of quality of life for people with systemic sclerosis across seven European countries: A cross-sectional study. Ann Rheum Dis 2018;77:1032-8.
17. Nolan CM, Delogu V, Maddocks M, et al. Validity, responsiveness and minimum clinically important difference of the incremental shuttlewalk in idiopathic pulmonary fibrosis: A prospective study. Thorax 2017.
18. Barker RE, Nolan C, Delogu V. The King's brief interstitial lung disease questionnaire: Response to pulmonary rehabilitation and minimal important difference. Am J Respir Crit Care Med 2017;195:A2849.